885229-27-6

Basic information

• Product Name: 4-Chloro-5-iodothieno[2,3-d]pyriMidine
• Synonyms: 4-Chloro-5-iodothieno[2,3-d]pyriMidine
• CAS NO: 885229-27-6
• Molecular Formula: C₆H₂ClIN₂S
• Molecular Weight: 296.51595
• Mol File: 885229-27-6.mol

Chemical Properties

• Boiling Point: 369.1±37.0 °C(Predicted)
• Appearance: /
• Density: 2 +-.0.06 g/cm3(Predicted)
• Storage Temp.: Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
• PKA: -0.20±0.40(Predicted)
• CAS DataBase Reference: 4-Chloro-5-iodothieno[2,3-d]pyriMidine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Chloro-5-iodothieno[2,3-d]pyriMidine(885229-27-6)
• EPA Substance Registry System: 4-Chloro-5-iodothieno[2,3-d]pyriMidine(885229-27-6)

Safety Data

• Hazardous Substances Data: 885229-27-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research and Development:
4-Chloro-5-iodothieno[2,3-d]pyrimidine is utilized as a building block for the synthesis of new drugs and pharmaceutical compounds. Its unique structure allows it to be a key component in the development of various biologically active molecules.
Used in Organic Synthesis:
4-Chloro-5-iodothieno[2,3-d]pyriMidine is also studied for its potential use in organic synthesis, where it can contribute to the creation of complex organic molecules with specific properties and functions.
Used in Material Science:
4-Chloro-5-iodothieno[2,3-d]pyrimidine has been explored for its applications in material science, where its distinctive structure can be employed to engineer new materials with tailored characteristics for various industries.

Upstream product

• 814918-95-1 5-bromo-4-chlorothieno[2,3-d]pyrimidine 
• 56844-12-3 6-bromo-4-chlorothieno[2,3-d]pyrimidine 
• 14080-50-3 thieno[2,3-d]pyrimidin-4(3H)one 
• 56844-40-7 6-bromothieno[2,3-d]pyrimidin-4(3H)-one 
• 4651-82-5 2-amino-3-cyanothiophene 

Downstream Products

• 1370338-71-8 4-chloro-5-(3-(methylsulfonyl)phenyl)thieno[2,3-d]pyrimidine 
• 1370338-31-0 2-methyl-5-(5-(3-(methylsulfonyl)phenyl)thieno[2,3-d]pyrimidin-4-ylthio)-1,3,4-oxadiazole 

Relevant articles and documents

Discovery of S64315, a Potent and Selective Mcl-1 Inhibitor

Myeloid cell leukemia 1 (Mcl-1) has emerged as an attractive target for cancer therapy. It is an antiapoptotic member of the Bcl-2 family of proteins, whose upregulation in human cancers is associated with high tumor grade, poor survival, and resistance to chemotherapy. Here we report the discovery of our clinical candidate S64315, a selective small molecule inhibitor of Mcl-1. Starting from a fragment derived lead compound, we have conducted structure guided optimization that has led to a significant (3 log) improvement of target affinity as well as cellular potency. The presence of hindered rotation along a biaryl axis has conferred high selectivity to the compounds against other members of the Bcl-2 family. During optimization, we have also established predictive PD markers of Mcl-1 inhibition and achieved both efficient in vitro cell killing and tumor regression in Mcl-1 dependent cancer models. The preclinical candidate has drug-like properties that have enabled its development and entry into clinical trials.

Macrocyclic MCL-1 inhibitors and methods of use

The present disclosure provides for compounds of Formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents for the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).

Structure-guided discovery of a selective mcl-1 inhibitor with cellular activity

Myeloid cell leukemia 1 (Mcl-1), an antiapoptotic member of the Bcl-2 family of proteins, whose upregulation when observed in human cancers is associated with high tumor grade, poor survival, and resistance to chemotherapy, has emerged as an attractive target for cancer therapy. Here, we report the discovery of selective small molecule inhibitors of Mcl-1 that inhibit cellular activity. Fragment screening identified thienopyrimidine amino acids as promising but nonselective hits that were optimized using nuclear magnetic resonance and X-ray-derived structural information. The introduction of hindered rotation along a biaryl axis has conferred high selectivity to the compounds, and cellular activity was brought on scale by offsetting the negative charge of the anchoring carboxylate group. The obtained compounds described here exhibit nanomolar binding affinity and mechanism-based cellular efficacy, caspase induction, and growth inhibition. These early research efforts illustrate drug discovery optimization from thienopyrimidine hits to a lead compound, the chemical series leading to the identification of our more advanced compounds S63845 and S64315.

MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE

The present disclosure provides for compounds of Formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).

MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE

The present disclosure provides for compounds of formula (I), wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of formula (I).

Inhibition of PIP4Kγ ameliorates the pathological effects of mutant huntingtin protein

The discovery of the causative gene for Huntington’s disease (HD) has promoted numerous efforts to uncover cellular pathways that lower levels of mutant huntingtin protein (mHtt) and potentially forestall the appearance of HD-related neurological defects.

NEW AMINOACID DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Compounds of formula (I): wherein R1, R2, R5, R6, R7, R12, X, Y, A, E and n are as defined in the description. Medicaments.

NEW THIENOPYRIMIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Compounds of formula (I): wherein R1, R2, R3, R4, R5, R6, R7, R12, X, A and n are as defined in the description.

COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF TREATING OR PREVENTING NEURODEGENERATIVE DISEASES OR DISORDERS

Disclosed are compounds of the formula (I): wherein R1, R2, X, Y, and Z as described herein, or pharmaceutically acceptable salts thereof, for use in treating or preventing neurodegenerative diseases and disorders such as Huntington'

Thieno-pyrimidine compounds having fungicidal activity

The present invention relates to thieno[2,3-d]-pyrimidine compounds having fungicidal activity.